GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology.
“We welcome award-winning immunologist Dr. Stone to the GigaGen team,” said Dave Johnson, Ph.D., CEO of GigaGen. “Dr. Stone brings with her a deep understanding of the tumor microenvironment and checkpoint inhibitors that is perfectly paired with our novel antibody discovery and engineering platform, Surge. Surge enables us to uncover new antibodies that have historically been missed by traditional discovery methods such as hybridoma, and with Dr. Stone’s expertise we look forward to identifying immuno-oncology drug candidates with the greatest potential to improve patient treatment.”
Read the full press release.